Innovation in Psychedelic Research: Dr. Danielle Schlosser’s Interview on Psychedelic Alpha
Josh Hardman from Psychedelic Alpha recently had a conversation with Dr. Danielle Schlosser, the co-founder and Chief Innovation Officer at mpathic, about the impact of our AI-powered platform on clinical trials. mpathic is at the forefront of using AI to navigate the complex landscape of psychedelic drug development, an area filled with potential but also numerous challenges.
A significant challenge in the field is selecting patient responders likely to benefit from these novel treatments. Dr. Schlosser discusses how mpathic’s technology aims to improve this selection process. By employing AI, the platform strives to make patient pre-selection more efficient, enhancing the likelihood of positive outcomes for trial participants.
Dr. Schlosser also touched on the essential role of technology in maintaining high standards of care throughout clinical trials. Beyond refining patient selection, mpathic’s AI enhances sponsor oversight and boosts the quality and consistency of psychosocial support and clinical outcome assessments. This approach helps ensure that participants receive the necessary care and support, moving beyond the traditional approaches found in many current clinical settings.
mpathic’s commitment to innovation in psychedelic drug development has attracted attention from the field’s leading players, such as atai Life Sciences. This partnership highlights a mutual recognition of AI’s potential to reshape the future of drug development and clinical trials, ensuring that advancements are not only groundbreaking in theory but also beneficial in practice.
The conversation between Josh Hardman and Dr. Danielle Schlosser offers valuable insights into the role of technology in improving healthcare and therapeutic interventions. As mpathic continues to lead with its innovative solutions, the potential to enhance what’s possible in drug development and patient care increases, signifying a future where the complexities of mental health interventions are addressed with more tailored, sophisticated technologies.
At mpathic, we are poised to not only address current needs in clinical trials and drug development but to also anticipate and tackle the challenges that lie ahead. Our work with AI in psychedelic research marks the beginning of this ambitious journey.
Read the entire interview here: Psychedelic Alpha interview
